Latest Conference Articles

January 21st 2017, 2:10am

Gastrointestinal Cancers Symposium (ASCO GI)

Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

January 21st 2017, 12:11am

Gastrointestinal Cancers Symposium (ASCO GI)

Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.

January 20th 2017, 10:45pm

Gastrointestinal Cancers Symposium (ASCO GI)

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

January 20th 2017, 5:52am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

January 20th 2017, 4:19am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

January 20th 2017, 1:18am

Gastrointestinal Cancers Symposium (ASCO GI)

​Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

January 18th 2017, 3:05am

Gastrointestinal Cancers Symposium (ASCO GI)

Switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy improved pathologic complete response rates in patients with esophageal and gastroesophageal junction cancers.

January 18th 2017, 2:37am

Gastrointestinal Cancers Symposium (ASCO GI)

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.

January 18th 2017, 2:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

December 10th 2016, 5:28am

San Antonio Breast Cancer Symposium

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

December 10th 2016, 5:15am

San Antonio Breast Cancer Symposium

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

December 10th 2016, 5:05am

San Antonio Breast Cancer Symposium

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

December 10th 2016, 3:31am

San Antonio Breast Cancer Symposium

The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

December 10th 2016, 3:16am

San Antonio Breast Cancer Symposium

Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.

December 10th 2016, 1:50am

San Antonio Breast Cancer Symposium

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

December 10th 2016, 1:49am

San Antonio Breast Cancer Symposium

A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.

December 10th 2016, 12:12am

San Antonio Breast Cancer Symposium

Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.

December 9th 2016, 11:33pm

San Antonio Breast Cancer Symposium

Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

December 9th 2016, 5:02am

San Antonio Breast Cancer Symposium

​Sara A. Hurvitz, MD, medical oncologist, associate professor of Medicine, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, UCLA, discusses the findings of the neoMONARCH trial, a neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole, which induced a response rate of 54.7% in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

December 9th 2016, 4:41am

San Antonio Breast Cancer Symposium

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.